Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News argenx SE ADR ARGX

Healthcare Biotechnology
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an... see more

Recent & Breaking News (NDAQ:ARGX)

argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia

GlobeNewswire September 20, 2017

argenx reports second quarter business update and half-year 2017 financial results

GlobeNewswire August 24, 2017

argenx announces publication in Nature Medicine of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116 for the treatment of dyslipidemia

GlobeNewswire August 23, 2017

argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results on August 24, 2017

GlobeNewswire August 17, 2017

argenx to Present at Wedbush PacGrow Healthcare Conference

GlobeNewswire August 8, 2017

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore)

GlobeNewswire July 7, 2017

argenx receives second preclinical milestone payment in collaboration with LEO Pharma

GlobeNewswire June 20, 2017

argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Malignant Lymphoma (ICML)

GlobeNewswire June 14, 2017

argenx to Present at JMP Securities Life Sciences Conference

GlobeNewswire June 13, 2017

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  June 12, 2017

argenx announces closing of NASDAQ IPO

GlobeNewswire May 23, 2017

argenx announces full exercise of underwriters' option to purchase additional ADSs

GlobeNewswire May 19, 2017

Nasdaq Welcomes argenx (Nasdaq: ARGX) to The Nasdaq Stock Market

GlobeNewswire May 18, 2017

argenx (Nasdaq: ARGX) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO

GlobeNewswire May 18, 2017